Haleon PLC Sponsored ADR (NYSE:HLN) Stock Holdings Boosted by WCM Investment Management LLC

WCM Investment Management LLC raised its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 34.7% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 422,487 shares of the company's stock after buying an additional 108,775 shares during the quarter. WCM Investment Management LLC's holdings in Haleon were worth $4,326,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC bought a new position in shares of Haleon during the fourth quarter valued at approximately $187,000. Bank of New York Mellon Corp grew its holdings in shares of Haleon by 29.8% during the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company's stock valued at $19,758,000 after purchasing an additional 475,934 shares during the last quarter. SVB Wealth LLC bought a new position in shares of Haleon during the fourth quarter valued at approximately $121,000. Jones Financial Companies Lllp grew its holdings in shares of Haleon by 57.2% during the fourth quarter. Jones Financial Companies Lllp now owns 162,187 shares of the company's stock valued at $1,547,000 after purchasing an additional 59,006 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of Haleon during the fourth quarter valued at approximately $353,000. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Stock Performance

HLN stock traded up $0.10 on Friday, reaching $10.36. The company's stock had a trading volume of 8,422,996 shares, compared to its average volume of 9,525,217. Haleon PLC Sponsored ADR has a 52 week low of $8.49 and a 52 week high of $11.42. The company has a market capitalization of $46.54 billion, a P/E ratio of 26.55, a price-to-earnings-growth ratio of 2.92 and a beta of 0.25. The firm has a fifty day moving average of $10.72 and a two-hundred day moving average of $10.15. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.98 and a quick ratio of 0.78.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on HLN. Wall Street Zen raised Haleon from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Barclays reaffirmed an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. BNP Paribas raised Haleon to a "strong-buy" rating in a report on Tuesday, May 27th. Morgan Stanley raised Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price for the company in a report on Friday, May 9th. Finally, BNP Paribas Exane raised Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective for the company in a report on Tuesday, May 27th. Five research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $12.33.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.